A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)

Phase 1Not Yet RecruitingNCT07600775

Merck Sharp & Dohme LLC14 enrolled

Overview

Researchers are studying MK-8527, a new medicine for preventing HIV-1 (human immunodeficiency virus type 1) infection and want to learn if MK-8527 can be given together with rifampin. Rifampin is commonly used to treat people with latent tuberculosis infection (LTBI). The main goal of this study is to learn what happens to MK-8527 in the body over time when given with and without the medication rifampin in participants with LTBI.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis

Interventions

MK-8527DRUG

Administered orally

RifampinDRUG

Administered orally

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has a diagnosis of untreated latent tuberculosis infection (LTBI) * Has no symptoms of active tuberculosis (TB) * Has never received treatment for TB or LTBI * Other than having LTBI, is in good health Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a diagnosis of LTBI made in the context of an outbreak/contact-tracing investigation * Has a current or anticipated immunocompromised state * Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases * Has a history of cancer (malignancy) * Has a history of active TB * Has positive test results for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus